The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis - Wikidata - wikimedia - TriplyDB

The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis

The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis

http://www.wikidata.org/entity/Q33724231

about

Targeting MicroRNA Function in Respiratory Diseases: Mini-Review Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension MicroRNAs in idiopathic pulmonary fibrosis: involvement in pathogenesis and potential use in diagnosis and therapeutics The code of non-coding RNAs in lung fibrosis MicroRNA-96 inhibits FoxO3a function in IPF fibroblasts on type I collagen matrix.RNA sequencing reveals a depletion of collagen targeting microRNAs in Dupuytren's disease.MicroRNAs as potential targets for progressive pulmonary fibrosis miR-27b inhibits fibroblast activation via targeting TGFβ signaling pathway.MicroRNA-27a-3p Is a Negative Regulator of Lung Fibrosis by Targeting Myofibroblast Differentiation.The coordinated roles of miR-26a and miR-30c in regulating TGFβ1-induced epithelial-to-mesenchymal transition in diabetic nephropathy.MicroRNA Mediating Networks in Granulosa Cells Associated with Ovarian Follicular Development Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions.Epigenetic targets for novel therapies of lung diseases.MicroRNA regulatory networks in idiopathic pulmonary fibrosis.A key role of microRNA-26a in the scar formation after glaucoma filtration surgery.miR-19a, -19b, and -26b Mediate CTGF Expression and Pulmonary Fibroblast Differentiation.Detecting the Molecular System Signatures of Idiopathic Pulmonary Fibrosis through Integrated Genomic Analysis TGF-β Signaling from Receptors to Smads.MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis.miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-β Receptor II.Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases.Novel Anti-fibrotic Therapies.MicroRNAs in mucosal inflammation.MicroRNA-26a inhibits TGF-β-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy.Microrna-26b attenuates monocrotaline-induced pulmonary vascular remodeling via targeting connective tissue growth factor (CTGF) and cyclin D1 (CCND1).MicroRNA-26b functions as a proapoptotic factor in porcine follicular Granulosa cells by targeting Sma-and Mad-related protein 4.MiR-26a contributes to the PDGF-BB-induced phenotypic switch of vascular smooth muscle cells by suppressing Smad1.A novel lnc-PCF promotes the proliferation of TGF-β1-activated epithelial cells by targeting miR-344a-5p to regulate map3k11 in pulmonary fibrosis.Role of MicroRNAs in TGF-β Signaling Pathway-Mediated Pulmonary Fibrosis.LncRNA PFL contributes to cardiac fibrosis by acting as a competing endogenous RNA of let-7d.MEKK1, JNK, and SMAD3 mediate CXCL12-stimulated connective tissue growth factor expression in human lung fibroblasts.Melatonin Protects against Lung Fibrosis by Regulating the Hippo/YAP Pathway.miR-26a suppresses EMT by disrupting the Lin28B/let-7d axis: potential cross-talks among miRNAs in IPF.MicroRNA-26a and -26b inhibit lens fibrosis and cataract by negatively regulating Jagged-1/Notch signaling pathway.miR-26a Potentially Contributes to the Regulation of Fatty Acid and Sterol Metabolism In Vitro Human HepG2 Cell Model of Nonalcoholic Fatty Liver Disease Molecular pathogenesis involved in human idiopathic pulmonary fibrosis based on an integrated microRNA‑mRNA interaction network

P2860

Q26766476-B4E4C1E3-DDCB-4BA2-B3EB-E225159860F6 Q26801345-10109C6B-0A8D-45F3-B028-C461E44F05DF Q28068338-467D50FF-817A-4A3B-81D1-C9EFCAAEF7A5 Q28386827-4BD23BAF-83A6-4005-81B8-9C3C0ED46E59 Q34356445-3E986205-D8D6-47FA-9107-35F3D9416695 Q36134941-267223F3-51C3-4CC9-8E32-447ED79961CA Q36249425-B3C48C23-BE75-4C5B-BB2D-6FCB6E6F66CA Q36251724-7BB8ECAE-01A5-4330-A5ED-D7338FC5BACF Q37088324-7666E417-E342-41F2-8477-D7F2DE929EDA Q37427986-ECB37A3F-4B90-4EC2-8FD8-7B7877E997A2 Q37681525-7738D952-5730-4821-BEA9-A165A25A23F3 Q38258015-F7DC3E08-2878-4E83-9A6D-F9FED21F0103 Q38275276-ED5BF9D4-9F05-4662-8894-E6F10338B93E Q38306947-3797B733-A10F-4529-BD4B-ACC722A97978 Q38689911-3057ECC9-A466-4B83-BD7C-6265A8C3BB4F Q38794416-C6954AC5-B34C-4237-ACA4-BDE7A65A5C6B Q38796898-09CE39AD-2D3C-45AC-A6C7-014C241AC1D0 Q38906099-778ADD39-2CBF-4AA1-AC1D-AB610F41F3CE Q38917573-7DBE85C3-974B-4DD3-B5FC-F05F4208B380 Q38993906-CD2818F7-3966-4118-ABFF-7053348D15BA Q39096514-6F593C6B-5DF7-4114-91C6-45EDB53C6088 Q39377055-6A976F42-3789-44AF-9F9B-13BB8524C4AC Q39446959-9B2EBBEA-8337-4109-BA77-7F6A3F35DC9E Q40848218-09AEC948-4E0E-44B3-A4AA-3E8417CD6BDF Q42317554-04B2DF03-0252-478A-BA40-9EE8A62B2883 Q44784192-0DEFAAB3-1CB3-4CB5-89B3-6475D3AF90D1 Q47104906-EEC646F5-71A7-4106-ACB3-C0F0B9A0312F Q47149080-06C70061-01B8-42D2-88F8-941A42DB90F2 Q47382571-3F4CEEC4-6A08-4AFF-84D4-86533A4D4761 Q49788031-5FAA6DC1-29F9-40EB-BABA-6E7558900B79 Q51418425-D3F43CE4-D7DC-404A-8B0A-2E751593E718 Q52593627-BFF2066C-E598-4DC4-ADDA-A58E67A45864 Q52667269-6DBDEDE1-11C2-40E6-9D21-7E6DCD61D904 Q52859357-63E6826B-75F6-45B4-8468-5573F8B78CEE Q58604344-D2C8D464-344F-4667-AF6A-327892CF7A9E Q58762351-3CB45799-CAC8-42FB-9A1E-29FDD3A7B6A8

P2860

The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis

http://www.wikidata.org/entity/Q33724231

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The antifibrotic effects and m ...... idiopathic pulmonary fibrosis

@ast

The antifibrotic effects and m ...... idiopathic pulmonary fibrosis

@en

type

label

The antifibrotic effects and m ...... idiopathic pulmonary fibrosis

@ast

The antifibrotic effects and m ...... idiopathic pulmonary fibrosis

@en

prefLabel

The antifibrotic effects and m ...... idiopathic pulmonary fibrosis

@ast

The antifibrotic effects and m ...... idiopathic pulmonary fibrosis

@en

P1433

Q33724231-03583210-0D22-4812-A5B0-3A42A7E51995

P1476

Q33724231-86D4B00C-8BCE-4DDA-A148-741F447E3F1E

P2093

Q33724231-0282924C-D5B6-431A-B8A1-AF391BFB0431

Q33724231-041B753D-91DC-4DBD-BC33-896B96ED40A0

Q33724231-0736CB2B-2351-489D-A15F-D1349FC00ECC

Q33724231-1468EEC5-2121-448A-BD81-1ABE1260EF3C

Q33724231-3943C585-C66E-4724-BF3F-6806678B166A

Q33724231-666008F6-67AA-4A2A-9021-BFD27AE18515

Q33724231-8B7DBB4E-0344-4B20-A93D-C81302BC74A9

Q33724231-90FD7594-AF98-4652-9514-945DA389BF4F

Q33724231-95403EC9-38DC-4438-A224-4FA729D32D2D

Q33724231-95F42DC3-90D6-40DB-8619-9BE17917C8B8

P2860

Q33724231-002E082C-505A-4CE9-9292-E39DD6197F2C

Q33724231-090AD36F-24C6-437E-8C54-05CBAAD80E0E

Q33724231-0EA78FE4-95C3-454C-8171-956129AEDE62

Q33724231-12EB2D1A-893E-4A0C-87C7-ABBA60EFA77C

Q33724231-1469D2CA-4CF8-43C5-9912-E7C9B9FCACF5

Q33724231-1B03E2BF-6890-42A0-A53C-A9A78E668699

Q33724231-24C7CA6B-A61E-4D27-834C-49EB34489F7A

Q33724231-2A065AC8-DF12-4BE6-A1B3-B9637F62441E

Q33724231-2D6399AC-6AFF-4FBB-AD5B-1D56D151217B

Q33724231-347BC43C-8CBF-49AB-922B-6AA80FF96F57

P304

Q33724231-441CB5B3-9E66-4F42-973A-4BE274720853

P31

Q33724231-E9EEA654-DEF6-4685-BDAC-EEEDD98C5B7B

P356

Q33724231-C1392AD1-F830-49B1-A434-1AF8BEB4024F

P433

Q33724231-7B4190A0-4705-4934-BFAF-0C0B02821503

P478

Q33724231-346156D3-2161-482C-BB30-1B40BB3E329F

P577

Q33724231-D1ECE920-25D6-4560-AA33-810EF944F356

P5875

Q33724231-8FB27D06-A685-4982-A615-F7C60CCB60A3

P698

Q33724231-6CCFE8DA-893D-4C8B-875F-8ECD477D6BBB

P921

Q33724231-31F45CCB-EA2D-474C-BEE8-448FB8255DD5

Q33724231-EF27874E-6DB1-430F-89ED-C2D33A0DA251

P932

Q33724231-5CBA56AB-9A53-4134-95B0-74AA19A257B7

P356

P1433

Molecular Therapy

P1476

The antifibrotic effects and m ...... idiopathic pulmonary fibrosis

@en

P2093

Baofeng Yang

http://www.w3.org/2001/XMLSchema#string

Chaoqian Xu

http://www.w3.org/2001/XMLSchema#string

Haihai Liang

http://www.w3.org/2001/XMLSchema#string

Hongli Shan

http://www.w3.org/2001/XMLSchema#string

Longtao Huangfu

http://www.w3.org/2001/XMLSchema#string

Samuel Gitau

http://www.w3.org/2001/XMLSchema#string

Tianyu Li

http://www.w3.org/2001/XMLSchema#string

Xuelian Li

http://www.w3.org/2001/XMLSchema#string

Yanjie Lu

http://www.w3.org/2001/XMLSchema#string

Ying Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition and role of let-7d in idiopathic pulmonary fibrosis

The basics of epithelial-mesenchymal transition

The myofibroblast: one function, multiple origins

MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation

Role of transforming growth factor beta in human disease

Myofibroblasts and mechano-regulation of connective tissue remodelling

Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines

Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway

Up-regulation of miR-26a promotes apoptosis of hypoxic rat neonatal cardiomyocytes by repressing GSK-3β protein expression

The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer

P304

1122-1133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2014.42

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260526095

http://www.w3.org/2001/XMLSchema#string

P698

24594795

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

4048895

http://www.w3.org/2001/XMLSchema#string